vs
Offerpad Solutions Inc.（OPAD）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是Offerpad Solutions Inc.的1.8倍（$200.5M vs $114.1M），ROGERS CORP同比增速更快（5.2% vs -34.5%），Offerpad Solutions Inc.自由现金流更多（$65.7M vs $1.1M），过去两年ROGERS CORP的营收复合增速更高（-3.3% vs -36.8%）
Offerpad Solutions Inc是美国知名房地产科技企业，专注于简化住宅房产交易流程，采用iBuyer模式直接向卖家收购房屋，完成翻新后挂牌出售，同时提供按揭、产权服务、灵活搬迁方案等配套服务，业务覆盖美国数十个州。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
OPAD vs ROG — 直观对比
营收规模更大
ROG
是对方的1.8倍
$114.1M
营收增速更快
ROG
高出39.8%
-34.5%
自由现金流更多
OPAD
多$64.6M
$1.1M
两年增速更快
ROG
近两年复合增速
-36.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $200.5M |
| 净利润 | — | $4.5M |
| 毛利率 | 7.0% | 32.2% |
| 营业利润率 | — | — |
| 净利率 | — | 2.2% |
| 营收同比 | -34.5% | 5.2% |
| 净利润同比 | 49.1% | 421.4% |
| 每股收益（稀释后） | — | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPADROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $114.1M | $201.5M | ||
| Q3 25 | $132.7M | $216.0M | ||
| Q2 25 | $160.3M | $202.8M | ||
| Q1 25 | $160.7M | $190.5M | ||
| Q4 24 | $174.3M | $192.2M | ||
| Q3 24 | $208.1M | $210.3M | ||
| Q2 24 | $251.1M | $214.2M |
净利润OPADROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $-11.6M | $8.6M | ||
| Q2 25 | $-10.9M | $-73.6M | ||
| Q1 25 | $-15.1M | $-1.4M | ||
| Q4 24 | $-17.3M | $-500.0K | ||
| Q3 24 | $-13.5M | $10.7M | ||
| Q2 24 | $-13.8M | $8.1M |
毛利率OPADROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 7.0% | 31.5% | ||
| Q3 25 | 7.0% | 33.5% | ||
| Q2 25 | 8.9% | 31.6% | ||
| Q1 25 | 6.5% | 29.9% | ||
| Q4 24 | 6.1% | 32.1% | ||
| Q3 24 | 8.2% | 35.2% | ||
| Q2 24 | 8.7% | 34.1% |
营业利润率OPADROG
| Q1 26 | — | — | ||
| Q4 25 | — | 3.5% | ||
| Q3 25 | -5.1% | 7.3% | ||
| Q2 25 | -4.9% | -33.3% | ||
| Q1 25 | -7.2% | -0.2% | ||
| Q4 24 | -7.8% | -6.6% | ||
| Q3 24 | -4.3% | 6.9% | ||
| Q2 24 | -3.9% | 5.3% |
净利率OPADROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | -8.7% | 4.0% | ||
| Q2 25 | -6.8% | -36.3% | ||
| Q1 25 | -9.4% | -0.7% | ||
| Q4 24 | -9.9% | -0.3% | ||
| Q3 24 | -6.5% | 5.1% | ||
| Q2 24 | -5.5% | 3.8% |
每股收益（稀释后）OPADROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | — | $0.20 | ||
| Q3 25 | $-0.37 | $0.48 | ||
| Q2 25 | $-0.39 | $-4.00 | ||
| Q1 25 | $-0.55 | $-0.08 | ||
| Q4 24 | $-0.64 | $-0.04 | ||
| Q3 24 | $-0.49 | $0.58 | ||
| Q2 24 | $-0.50 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.5M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $38.2M | $1.2B |
| 总资产 | $154.8M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OPADROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $26.5M | $197.0M | ||
| Q3 25 | $31.0M | $167.8M | ||
| Q2 25 | $22.6M | $157.2M | ||
| Q1 25 | $30.8M | $175.6M | ||
| Q4 24 | $43.0M | $159.8M | ||
| Q3 24 | $48.5M | $146.4M | ||
| Q2 24 | $56.9M | $119.9M |
股东权益OPADROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $38.2M | $1.2B | ||
| Q3 25 | $39.9M | $1.2B | ||
| Q2 25 | $24.5M | $1.2B | ||
| Q1 25 | $34.2M | $1.3B | ||
| Q4 24 | $47.7M | $1.3B | ||
| Q3 24 | $64.7M | $1.3B | ||
| Q2 24 | $77.6M | $1.3B |
总资产OPADROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $154.8M | $1.4B | ||
| Q3 25 | $223.5M | $1.4B | ||
| Q2 25 | $268.0M | $1.5B | ||
| Q1 25 | $274.5M | $1.5B | ||
| Q4 24 | $313.1M | $1.5B | ||
| Q3 24 | $338.5M | $1.5B | ||
| Q2 24 | $406.6M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.8M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $65.7M | $1.1M |
| 自由现金流率自由现金流/营收 | 57.6% | 0.5% |
| 资本支出强度资本支出/营收 | 0.9% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流OPADROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $66.8M | $46.9M | ||
| Q3 25 | $40.0M | $28.9M | ||
| Q2 25 | $-13.5M | $13.7M | ||
| Q1 25 | $-10.2M | $11.7M | ||
| Q4 24 | $20.8M | $33.7M | ||
| Q3 24 | $39.6M | $42.4M | ||
| Q2 24 | $-54.4M | $22.9M |
自由现金流OPADROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $65.7M | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | $-13.6M | $5.6M | ||
| Q1 25 | $-11.2M | $2.1M | ||
| Q4 24 | $15.4M | $18.3M | ||
| Q3 24 | $38.7M | $25.2M | ||
| Q2 24 | $-54.4M | $8.8M |
自由现金流率OPADROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 57.6% | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | -8.5% | 2.8% | ||
| Q1 25 | -7.0% | 1.1% | ||
| Q4 24 | 8.9% | 9.5% | ||
| Q3 24 | 18.6% | 12.0% | ||
| Q2 24 | -21.7% | 4.1% |
资本支出强度OPADROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.9% | 2.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.1% | 4.0% | ||
| Q1 25 | 0.6% | 5.0% | ||
| Q4 24 | 3.1% | 8.0% | ||
| Q3 24 | 0.4% | 8.2% | ||
| Q2 24 | 0.0% | 6.6% |
现金转化率OPADROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
